NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $0.62 +0.00 (+0.47%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.63 +0.00 (+0.72%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About InspireMD Stock (NYSE:NSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InspireMD alerts:Sign Up Key Stats Today's Range$0.61▼$0.6350-Day Range$0.62▼$0.9852-Week Range$0.60▼$2.57Volume65,699 shsAverage Volume140,796 shsMarket Capitalization$28.94 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company Overview InspireMD, Inc. (NYSE:NSPR) is a medical device company focused on developing and commercializing products for the treatment of vascular disease. The company’s primary focus is carotid artery disease, a condition in which plaque buildup can restrict blood flow and increase the risk of stroke. Its principal product is the CGuard Embolic Prevention System (EPS), a carotid stent system that combines a self-expanding stent with a fine mesh layer called MicroNet. The design is intended to stabilize plaque, reduce plaque protrusion through the stent, and help limit the release of embolic material during and after carotid artery procedures. InspireMD has also pursued regulatory clearances and commercial opportunities for its technology in international markets, including Europe and other regions, while seeking broader adoption in the United States. Founded in 2005 and based in Tel Aviv, Israel, InspireMD serves hospitals, physicians, and patients through a business focused on minimally invasive vascular interventions. Its products are designed for use by interventional cardiologists, vascular specialists, and other clinicians treating carotid and related vascular conditions.AI Generated. May Contain Errors. Read More Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSPR Stock News HeadlinesInspireMD (NYSE:NSPR) versus Edwards Lifesciences (NYSE:EW) Head-To-Head SurveySeptember 24, 2026 | americanbankingnews.comInspireMD Aligns Warrants With Anticipated CGuard Prime FDA DecisionSeptember 21, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)InspireMD Inc.: InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 MillionSeptember 21, 2026 | finanznachrichten.deInspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 MillionSeptember 21, 2026 | globenewswire.comInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comInspireMD, Inc. (NSPR) latest stock news and headlines – Yahoo FinanceSeptember 3, 2026 | uk.finance.yahoo.comInspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comSee More Headlines NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $1.78 at the beginning of the year. Since then, NSPR stock has decreased by 65.0% and is now trading at $0.6225. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) released its earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative trailing twelve-month return on equity of 69.42%. When did InspireMD IPO? InspireMD (NSPR) raised $10,000 in an IPO on Friday, May 21st 2021. The company issued 2,000,000 shares at a price of $0.00-$0.01 per share. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/12/2024Today10/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:NSPR CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees127Year FoundedN/APrice Target and Rating Average Price Target for InspireMD$4.50 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+622.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.92 million Net Margins-413.96% Pretax Margin-413.00% Return on Equity-69.42% Return on Assets-57.68% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.05 Sales & Book Value Annual Sales$10.84 million Price / Sales2.67 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.34Miscellaneous Outstanding Shares46,489,000Free Float18,332,000Market Cap$28.94 million OptionableOptionable Beta0.84 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:NSPR) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
